Other targeted agents, such as Bruton's tyrosine kinase inhibitor (BTKi) and B‐cell lymphoma‐2 inhibitor (BCL‐2i), were also used for R/R NHL patients. This evidence concerns the gene BTK and non-Hodgkin lymphoma.